Dermatologic Medication in Pregnancy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
List of Union Reference Dates A
Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov. -
Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre, -
Lamisil Versus Clotrimazole in the Treatment of Vulvovaginal Candidiasis
Volume 5 Number 1 (March 2013) 86-90 Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis Ali Zarei Mahmoudabadi1,2, Mahin Najafyan3, Eskandar Moghimipour4, Maryam Alwanian1, Zahra Seifi1 1Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3Department of Obstetric and Genecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Received: March 2012, Accepted: October 2012. ABSTRACT Background and Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole. Materials and Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared. Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and, 6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week. -
Download Product Insert (PDF)
PRODUCT INFORMATION Isoconazole (nitrate) Item No. 30100 CAS Registry No.: 24168-96-5 Cl Formal Name: 1-[2-(2,4-dichlorophenyl)-2-[(2,6- dichlorophenyl)methoxy]ethyl]-1H- imidazole, mononitrate Synonyms: Adestan G 100, R 15454 Cl Cl MF: C18H14Cl4N2O • HNO3 FW: 479.1 N N Purity: ≥98% O Supplied as: A solid Storage: -20°C • HNO3 Cl Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Isoconazole (nitrate) is supplied as a solid. A stock solution may be made by dissolving the isoconazole (nitrate) in the solvent of choice, which should be purged with an inert gas. Isoconazole (nitrate) is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of isoconazole (nitrate) in these solvents is approximately 10 mg/ml. Isoconazole (nitrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, isoconazole (nitrate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Isoconazole (nitrate) has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Isoconazole is an imidazole with antimicrobial activity.1 It is active against clinical isolates of Candida species, including C. albicans, C. parapsilosis, C. tropicalis, C. krusei, and C. guilliermondii with MIC values ranging from 0.12 to 2 μg/ml. It is also active against the fungi T. mentagrophytes and T. rubrum when used at a concentration of 0.1 µg/ml and the bacteria C. -
Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmani
Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmanial CYP5122A1 and CYP51 Enzymes Yiru Jin1, Mei Feng1, Michael Zhuo Wang1 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA CYP5122A1 is a novel cytochrome P450 (CYP) enzyme that is essential for the survival of Leishmania donovani, a major causative agent for human visceral leishmaniasis. Recent studies suggest that CYP5122A1 plays an important role as sterol 4-demethylase in ergosterol biosynthesis by Leishmania. Thus, CYP5122A1 inhibitors may represent a new therapeutic approach against the devastating infectious disease. To evaluate the effects of antifungal azoles on CYP5122A1, a panel of twenty marketed antifungal azoles (bifonazole, butoconazole, clotrimazole, econazole, efinaconazole, fenticonazole, fluconazole, isavuconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, ravuconazole, sertaconazole, sulconazole, terconazole, tioconazole, voriconazole) were screened for inhibition of CYP5122A1, as well as the lanosterol 14α-demethylase CYP51, using a fluorescence-based inhibition assay. All twenty azoles were potent inhibitors of leishmanial CYP51 with IC50 ranging from 0.031 to 0.084 M, whereas their inhibitory potencies against CYP5122A1 were much lower (0.25 to 12 M). Ravuconazole was identified as a selective CYP51 inhibitor with an IC50 value of 0.048 M and selectivity index of 250 against CYP5122A1. Interestingly, the imidazole class of antifungal azoles showed stronger inhibition against CYP5122A1 compared with the triazole class. These results can provide insights toward rational drug design of CYP5122A1 inhibitors. Future studies will attempt to obtain X-ray crystal structures of several select protein-ligand complexes and confirm the proposed biochemical roles of CYP5122A1 and CYP51 by treating parasites with selective inhibitors, followed by HPLC-MS/MS-based sterol analysis. -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole -
Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts. -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%). -
Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01 -
(Oral and Vaginal) Therapy for Recurrent Vulvovaginal Candidiasis: a Systematic Review Protocol
Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2018-027489 on 22 May 2019. Downloaded from Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol Juliana Lírio,1 Paulo Cesar Giraldo,2 Rose Luce Amaral,2 Ayane Cristine Alves Sarmento,3 Ana Paula Ferreira Costa,3 Ana Katherine Gonçalves3 To cite: Lírio J, Giraldo PC, ABSTRACT Strengths and limitations of this study Amaral RL, et al. Antifungal Introduction Vulvovaginal candidiasis (VVC) is frequent (oral and vaginal) therapy in women worldwide and usually responds rapidly to for recurrent vulvovaginal ► Two independent reviewers will select studies, ex- topical or oral antifungal therapy. However, some women candidiasis: a systematic tract data without different variables and assess develop recurrent vulvovaginal candidiasis (RVVC), which review protocol. BMJ Open the risk of bias, to indicate through evidence-based 2019;9:e027489. doi:10.1136/ is arbitrarily defined as four or more episodes every medicine if there is a more effective antifungal ther- bmjopen-2018-027489 year. RVVC is a debilitating, long-term condition that can apeutic regimen for the treatment of recurrent vul- severely affect the quality of life of women. Most VVC is Prepublication history for vovaginal candidiasis. ► diagnosed and treated empirically and women frequently this paper is available online. ► There may be a limitation of outcome from treat- To view these files, please visit self-treat with over-the-counter medications that could ment variation, routes of administration, different the journal online (http:// dx. doi. contribute to an increase in the antifungal resistance. The doses and quality of the randomised trials used in org/ 10. -
Oxiconazole Nitrate (BANM, USAN, Rinnm) Tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina
544 Antifungals Port.: Mycostatin; S.Afr.: Candacide; Canstat; Mycostatin; Nystacid; Singa- Preparations Profile pore: Mycostatin†; Spain: Mycostatin; Swed.: Mycostatin; Switz.: Mycos- Parconazole is an antifungal that has been used as the hydrochlo- tatine; Thai.: Lystin†; Mycostatin; Turk.: Fungostatin; Mikostatin; UAE: Proprietary Preparations (details are given in Part 3) ride in the treatment of gastrointestinal candidiasis in veterinary Mikostat; UK: Nystamont†; Nystan; USA: Mycostatin; Nilstat; Nystop; Pedi- Dri; Venez.: Micostatin; Nistafesa†; Romalina†. Austria: Afongan; Fr.: Fongamil; Fongarex; Gr.: Fongamil; Hung.: Mikogal; medicine. Mex.: Afongan; Port.: Afongan†; Fongamil; Rus.: Mikogal (Микогал). Multi-ingredient: Arg.: Bacticort Complex; Bexon; Biotaer Gamma†; Bi- otaer Nebulizable; Dermadex NN; Farm-X Duo; Fasigyn Nistatina; Flagys- tatin; Kenacomb; Linfol; Min O; Naxo TV; Neocolpoben†; Nistinol; O-Biol; Pentamycin O-Biol P; Pelvicillin NF; Polygynax; Terra-Cortril Nistatina†; Tratomax; Aus- Oxiconazole Nitrate (BANM, USAN, rINNM) tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina. Zinkoxid; Topsym polyvalent; Belg.: Eoline†; Mycolog; Polygynax†; Braz.: Nitrato de oxiconazol; Oxiconazole, Nitrate d’; Oxiconazoli Ni- Benzevit; Bio-Vagin; Colpagex N; Colpatrin; Colpist; Colpistar; Colpistatin; Пентамицин tras; Ro-13-8996; Ro-13-8996/001; Ro-13-8996/000 (oxicona- Colpolase; Dermodex; Dermokin; Donnagel; Flagyl Nistatina; Fungimax; Gi- C35H58O12 = 670.8. nec†; Ginestatin; Gynax-N; Londerm-N; Minegyl C/Nistatina†; Mud; Nax- zole); SGD-301-76; ST-813. 2′,4′-Dichloro-2-imidazol-1-ylace- CAS — 6834-98-6. ogin Composto; Neolon-D; Nistazol†; Omcilon A M; Onciplus; Oxyderme; tophenone (Z)-O-(2,4-dichlorobenzyl)oxime mononitrate. Poliginax; Tricolpex; Tricomax; Trivagel N; Vagi Biotic; Vagimax; Vagitrin-N; ATC — G01AA11. Canad.: Flagystatin; Kenacomb†; ratio-Triacomb; Triacomb†; Viaderm-KC; Оксиконазола Нитрат ATC Vet — QG01AA11.